(A–C) Prodrug (Metronidazole, Mtz) inducible ablation of rod photoreceptors in rho:YFP-NTR larvae. (A) In vivo confocal images of a rho:YFP-NTR larvae showing transgene expression specificity and …
Mtz titration test.
(A–C) Immunohistological analysis of rod and cone photoreceptor markers in seven dpf rho:YFP-NTR larvae retinas treated ± 2.5 mM Mtz from 5 to 7 dpf. Representative whole retina and zoomed images of …
(A) Diagram of confirmation assay protocol (see Figure 1D for further details). (B) Box plots of rod cell survival effects of eleven confirmed lead compounds (arrayed by level of neuroprotection) …
Lead compound confirmation.
(A) Box plots of NTR inhibition activity (relative to NTR alone control, set at 100%) of lead compounds tested at 300 or 50 μM (see B) using an in vitro assay of CB1954 prodrug reduction kinetics. …
Compound effects on NTR activity.
(A) Diagram of rod cell neogenesis assay protocol. Transgenic rho:YFP-NTR larvae were treated with individual lead compounds from 5 to 7 dpf to test for effects on rod photoreceptor neogenesis; …
Compound effects on rod cell neogenesis.
(A) Diagram of rod cell regeneration assay protocol. Transgenic rho:YFP-NTR were exposed to 10 mM Mtz from 5 to 6 dpf, then treated with individual lead compounds from 6 to 9 dpf. YFP signals were …
Compound effects on rod cell regeneration.
Representative 7 dpf in vivo confocal images of YFP-expressing rod cells in an ablated control (+Mtz), non-ablated control (-Mtz), and in Mtz-exposed retinas treated with lead compounds from 5 to 7 …
Box plots of lead compound effects on YFP volumes per image stack across conditions. All conditions resulted in a statistically significant increase in YFP volume relative to Mtz-ablated controls. …
YFP quantification - intensity.
(A) Representative 7 dpf in vivo confocal images of YFP-expressing rod cells in an ablated control (+Mtz), non-ablated control (-Mtz), and in Mtz-exposed rho: YFP-NTR2.0 retinas treated with lead …
YFP quantification - volume per cell.
(A) Primary photoreceptor survival assay protocol. (B) Box plots of photoreceptor survival effects of lead compounds and the positive control compound (POS). Statistically significant survival …
Compound tests of mouse photoreceptor culture - thapsigargin assay.
A) Diagram of primary photoreceptor survival assay protocol. Primary retinal cells were isolated from QRX mice and cultured for 2 days in tunicamycin (an ER stressor that induces cell death) and …
Quantification of mouse photoreceptor assay - tunicamycin-induced cell death.
(A–B) Lead compounds were tested individually and in pairs for survival effects in primary photoreceptor cells isolated from QRX mice as per Figure 4. Box plots and summary tables (below plots) show …
Paired drug tests - mouse photoreceptor cultures.
(A) Diagram of rd1 explant photoreceptor survival assay protocol. Retinal explants were isolated at postnatal day 10 (P10) and cultured for eleven days in lead compounds at three different …
Compound tests - rd1 mouse retinal explants.
(A) In vitro release kinetics of a long-release DHA formulation (DHA encapsulated in PLGA polymer microparticles, PLGA-DHA) in phosphate buffered saline containing 0.1% DMSO (pH 7.4) at 37°C (Figure …
PLGA-DHA in vitro release kinetics.
Box plots of rod cell survival effects of eight PARP inhibitors (green), a necroptosis inhibitor (blue), four apoptosis inhibitors (magenta), and three Tdp1 inhibitors (orange) in Mtz-treated rho:YFP…
Cell death inhibitor assay.
Box plots of rod cell survival effects of BMN (PARP inhibitor) and NEC (necroptosis inhibitor) tested alone and in pairs at three different concentrations in rho:YFP-NTR zebrafish larvae (assays …
Paired cell death inhibitor assay.
(A) Box plots of rod cell survival effects of CRISPR/Cas9-based knockdown of key cell death pathway genes: parp1 (parthanatos), ripk1l (necroptosis), casp3a and casp3b (apoptosis), as well as tdp1 …
Quantification of PAR accumulation.
(A) Representative intravital whole retina confocal image stacks of gene knockdown effects on YFP-expressing rod cell numbers in Mtz-treated fish (+Mtz, i.e. effects on NTR/Mtz-mediated cell death) …
qPCR confirmation of gene knockdown.
(A) Box plots of rod cell survival effects of five lead compounds and a PARP inhibitor control (BMN) in Mtz-treated rho:YFP-NTR zebrafish larvae in which parp1 expression was knocked down, assays …
Compound effects following gene knockdown.
Box plots of rod cell survival effects of seven lead compounds tested alone and in pairs in rho:YFP-NTR zebrafish larvae (assays performed as per confirmation tests, see Figure 2A). To test for …
Paired compound tests.
Common names, IUPAC names, abbreviations, PubChem CID, and chemical structures of confirmed lead compounds listed in order of efficacy.
Common and IUPAC names | Abbr. | PubChem CID | Structure |
---|---|---|---|
Warfarin 4-hydroxy-3-(3-oxo-1-phenylbutyl)chromen-2-one | WAR | 54678486 | ![]() |
Cloxyquin 5-Chloro-8-hydroxyquinoline | CLO | 2817 | ![]() |
Ciclopirox olamine 2-aminoethanol;6-cyclohexyl-1-hydroxy-4-methylpyridin-2-one | CPO | 38911 | ![]() |
Miconazole 1-[2-(2,4-dichlorophenyl)−2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole | MIC | 4189 | ![]() |
Zinc pyrithione zinc;1-oxidopyridin-1-ium-2-thiolate | ZPT | 26041 | ![]() |
Dihydroartemisinin (4S,5R,9R,10S,12R,13R)−1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-ol | DHA | 456410 | ![]() |
Chloroxine 5,7-dichloroquinolin-8-ol | CHL | 2722 | ![]() |
Calcimycin 5-(methylamino)−2-[[(2S,3R,5R,8S,9S)−3,5,9-trimethyl-2-[1-oxo-1-(1H-pyrrol-2-yl)propan-2-yl]−1,7-dioxaspiro[5.5]undecan-8-yl]methyl]−1,3-benzoxazole-4-carboxylic acid | CAL | 40486 | ![]() |
Sulindac 2-[(3Z)−6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid | SUL | 1548887 | ![]() |
Artemesinin (1R,4S,5R,8S,9R,12S,13R)−1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-one | ART | 68827 | ![]() |
Cortexolone (8R,9S,10R,13S,14S,17R)−17-hydroxy-17-(2-hydroxyacetyl)−10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one | COR | 440707 | ![]() |
Results of 13 target-based HTS screens, with '+' indicating inhibitory activity of lead compounds. Lead compound abbreviations: WAR, Warfarin; CLO, Cloxyquin; CPO, Ciclopirox olamine; MIC, …
Drug\path | Tdp1 | Rorc | AR | TR | VDR | ER | AhR | GR | P53 | Dopa | HIF1 | SHH | COX |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
WAR | + | ||||||||||||
MIC | + | + | + | + | + | ||||||||
CLO | + | + | + | + | + | + | + | ||||||
CPO | + | + | + | + | + | + | + | + | + | ||||
ZPT | + | + | + | + | + | + | + | + | + | + | |||
DHA | + | + | + | + | |||||||||
CHL | + | + | + | + | + | + | + | + | + | ||||
CAL | + | + | + | ||||||||||
SUL | + | + | + | ||||||||||
ART | + | + | |||||||||||
COR | + | + |
Cell death Pathway | Compound name (abbrv.) | Target(s) and Relative Activity (+) | Conc. [µM] | Effect (%) |
---|---|---|---|---|
Parp-dependent (Parthantos or cGMP-dependent) | AG-14361 (AG) | Parp1+++ | 64 | 9 |
NMS-P118 (NMS) | Parp1++ | 8 | 16 | |
Talazoparib (BMN) | Parp1 ++++ | 0.5 | 14 | |
Veliparib (ABT) | Parp1+++, 2+++ | 64 | 9 | |
Olaparib (Ola) | Parp1+++, 2++++ | 32 | 9 | |
E7449 | Parp1++++, 2++++ | 1 | 20 | |
Niraparib (MK) | Parp1+++, 2+++ | 32 | 11 | |
Rucaparib (RUC) | pan-Parp++++ | 32 | 17 | |
Necroptosis | Necrostatin-1 (NEC) | Rip1k++ | 64 | 17 |
Apoptosis | Ac-DEVD-CHO (AC) | Caspase 1+++, 2+, 3++++, 4++, 5++, 6+++, 7+++, 8++++, 9++, 10+++ | 0.5 | 3 |
Caspase3/7 inhibitor I (CASI) | Caspase 3++, 7++, 9+ | 0.5 | 1 | |
Caspase three inhibitor VII (CASVII) | Caspase 3+++ | 1 | 2 | |
Tdp1 (DNA repair) | Paromomycin (PM) | Tdp1+ | 20 | 10 |
Thiostrepton (ThS) | Tdp1+ | 100 | 10 | |
Methyl-3,4-dephostatin (MD) | Tdp1++ | 0.16 | 3 |
Reagent type (species) or resource | Designation | Source or reference |
---|---|---|
Transgenic zebrafish, Danio rerio (AB; roy) | Tg(rho:YFP-Eco.NfsB)gmc500; mpv17a9 (rho:YFP-NTR) | RRID # #:ZFIN_ZDB-GENO-190617–10 |
Transgenic zebrafish Danio rerio (AB; roy) | Tg(rho:GAP-YFP-2A-nfsB_Vv F70A/F108Y)jh405; mpv17a9 (rho:YFP-NTR2.0) | ZFIN ID pending; Mumm lab |
E. coli | BL21(DE3) Competent Cells | emdmillipore.com: 69450 |
Mutant mouse Mus musculus | Pde6brd1 (rd1) | RRID #:MGI:5902961 |
Mutant mouse Mus musculus (C57BL/6J) | Pde6brd10 (rd10) | RRID # #:IMSR_JAX:004297 |
Transgenic mouse Mus musculus (SJL/J) | QRX-IRES-EGFP | Zack lab |
Antibody | Anti-Arrestin3a (α-Arr3a; zpr-1) Mouse monoclonal (1:200 dilution) | RRID #:AB_10013803 |
Antibody | Anti-Rhodopsin (α-Rho; 1d1) Mouse monoclonal - 1:100 dilution | ZDB-ATB-081229–13 |
Antibody | Ab-4C12 (aka, 4C12) Mouse monoclonal - 1:50: dilution | ZDB-ATB-090506–2 |
Antibody | Anti-Mouse IgG (H+L), Alexa 647 Goat polyclonal - 1:1000 dilution | RRID #:AB_2338902 |
Antibody | Anti-Cone Arrestin (mouse) Rabbit polyclonal - 1:1000 dilution | RRID #:AB_1163387 |
Antibody | Anti-Retinal S antigen (S128) Mouse monoclonal - 1:1000 dilution | RRID #:AB_2747776 |
Antibody | Anti-PAR (human) Recombinant Antibody - 1:2000 dilution | PMID:30385548 |
Antibody | Anti-Human IgG (Fab')2 (HRP) Goat polyclonal - 1:10000 dilution | RRID #:AB_1951105 |
Antibody | Anti-beta-Actin-HRP Mouse monoclonal - 1:20000 dilution | RRID #:AB_262011 |
Chemical compound | 17-(Allylamino)−17-demethoxygeldanamycin (17-AAG) | CAS #: 75747-14-7 |
Chemical compound | 17β-Estradiol | CAS #: 50-28-2 |
Chemical compound | 3-Hydroxybenzylhydrazine dihydrochloride | CAS #: 81012-99-9 |
Chemical compound | 6,7-Dihydroxyflavone | CAS #: 38183-04-9 |
Chemical compound | Acacetin | CAS #: 480-44-4 |
Chemical compound | Ac-DEVD-CHO (AC) | CAS #: 169332-60-9 |
Chemical compound | AG-14361 | CAS #: 328543-09-5 |
Chemical compound | Alpha-lipoic acid | CAS #: 1077-28-7 |
Chemical compound | Alpha-tochopherol | CAS #: 10191-41-0 |
Chemical compound | Aluminum chloride hexahydrate | CAS #: 7784-13-6 |
Chemical compound | Artemisinin (ART) | CAS #: 63968-64-9 |
Chemical compound | Ascorbic acid | CAS #: 50-81-7 |
Chemical compound | Calcimycin (CAL) | CAS #: 52665-69-7 |
Chemical compound | Calpastatin peptide | sigmaaldrich.com: SCP0063 |
Chemical compound | Calpeptin | CAS #: 117591-20-5 |
Chemical compound | Caspase-3 Inhibitor VII (CASVII) | CAS #: 745046-84-8 |
Chemical compound | Caspase-3/7 Inhibitor I (CASI) | CAS #: 1110670-49-9 |
Chemical compound | Chloroxine (CHL) | CAS #: 773-76-2 |
Chemical compound | Ciclopirox olamine (CPO) | CAS #: 41621-49-2 |
Chemical compound | Clonidine | CAS #: 4205-90-7 |
Chemical compound | Clopidogrel sulfate | CAS #: 120202-66-6 |
Chemical compound | Cloxyquine (CLO) | CAS #: 130-16-5 |
Chemical compound | Compactin | CAS #: 73573-88-3 |
Chemical compound | Cortexolone (COR) | CAS #: 152-58-9 |
Chemical compound | D-(-)-Norgestrel | CAS #: 797-63-7 |
Chemical compound | Danthron | CAS #: 117-10-2 |
Chemical compound | DAPI dihydrochloride | CAS #: 28718-90-3 |
Chemical compound | Deltaline | CAS #: 6836-11-9 |
Chemical compound | Dexamethasone | CAS #: 50-02-2 |
Chemical compound | Diazepam | CAS #: 439-14-5 |
Chemical compound | Digoxin | CAS #: 20830-75-5 |
Chemical compound | Dihydroartemisinin | CAS #: 71939-50-9 |
Chemical compound | E7449 | CAS #: 1140964-99-3 |
Chemical compound | Entinostat | CAS #: 209783-80-2 |
Chemical compound | Escitalopram oxalate | CAS #: 219861-08-2 |
Chemical compound | Eupatorin | CAS #: 855-96-9 |
Chemical compound | Hoechst 33342 | CAS #: 23491-52-3 |
Chemical compound | Hydroquinone | CAS #: 123-31-9 |
Chemical compound | Indomethacin | CAS #: 53-86-1 |
Chemical compound | Isopropamide Iodide | CAS #: 71-81-8 |
Chemical compound | Isoxsuprine hydrochloride | CAS #: 579-56-6 |
Chemical compound | Lactulose | CAS #: 4618-18-2 |
Chemical compound | Leucovorin Calcium | CAS #: 1492-18-8 |
Chemical compound | Levobetaxolol | CAS #: 93221-48-8 |
Chemical compound | Lobeline sulfate | CAS #: 134-64-5 |
Chemical compound | Lovastatin | CAS #: 75330-75-5 |
Chemical compound | Magnesium gluconate | CAS #: 3632-91-5 |
Chemical compound | Menadione | CAS #: 58-27-5 |
Chemical compound | Mercaptamine hydrochloride | CAS #: 156-57-0 |
Chemical compound | Methyl-3,4-dephostatin (MD) | PubChem SID #: 24278575 |
Chemical compound | Metronidazole (MTZ) | CAS #: 443-48-1 |
Chemical compound | Miconazole (MIC) | CAS #: 22916-47-8 |
Chemical compound | MnTBAP | CAS #: 55266-18-7 |
Chemical compound | Myriocin | CAS #: 35891-70-4 |
Chemical compound | Myrrh oil | UPC #: 640791683602 |
Chemical compound | N-Acetyl-L-cysteine (NAC) | CAS #: 616-91-1 |
Chemical compound | Nalidixic acid | CAS #: 389-08-2 |
Chemical compound | NCS-382 | CAS #: 520505-01-5 |
Chemical compound | Necrostatin-1 (NET) | CAS #: 4311-88-0 |
Chemical compound | Niraparib (MK) | CAS #: 1038915-60-4 |
Chemical compound | NMS-P118 | CAS #: 1262417-51-5 |
Chemical compound | N-tert-Butyl-α-(2-sulfophenyl)nitrone | CAS #: 73475-11-3 |
Chemical compound | Olaparib (OLA) | CAS #: 763113-22-0 |
Chemical compound | Panobinostat | CAS #: 404950-80-7 |
Chemical compound | Paromomycin (PM) | CAS #: 1263-89-4 |
Chemical compound | PLGA | CAS #: 26780-50-7 |
Chemical compound | Pseudoephedrine, (1S,2S)-(+)- | CAS #: 90-82-4 |
Chemical compound | Retinoic acid (RA) | CAS #: 302-79-4 |
Chemical compound | Rofecoxib | CAS #: 162011-90-7 |
Chemical compound | Romidepsin | CAS #: 128517-07-7 |
Chemical compound | Rosiglitazone | CAS #: 122320-73-4 |
Chemical compound | Rucaparib (RUC) | CAS #: 283173-50-2 |
Chemical compound | Streptomycin sulfate | CAS #: 3810-74-0 |
Chemical compound | Sulindac (SUL) | CAS #: 38194-50-2 |
Chemical compound | Sunitinib | CAS #: 557795-19-4 |
Chemical compound | Talazoparib (BMN) | CAS #: 1207456-01-6 |
Chemical compound | thapsigargin | CAS #: 67526-95-8 |
Chemical compound | Thiostrepton (ThS) | CAS #: 1393-48-2 |
Chemical compound | tunicamycin | CAS #: 11089-65-9 |
Chemical compound | Veliparib (ABT) | CAS #: 912444-00-9 |
Chemical compound | Vorinostat | CAS #: 149647-78-9 |
Chemical compound | Warfarin (WAR) | CAS #: 81-81-2 |
Chemical compound | Xanthurenic acid | CAS #: 59-00-7 |
Chemical compound | Zinc pyrithione (ZPT) | CAS #: 13463-41-7 |
Software, algorithm | Software for large-scale in vivo screen data processing (R v3.3.1, R Studio v0.99.903, and the ARQiv2 package) | https://github.com/mummlab/ARQiv2 |
Software, algorithm | Thermo Scientific HCS Studio Cell Analysis Software | Customized for this project |
Database | CRISPRScan | https://www.crisprscan.org/ |
Statistics of Mtz titration assay.
(a) Statistical summary of Mtz titration assay in rho:YFP-NTR zebrafish larvae - Figure 1B. Survival effects (normalized YFP, %), 95% confidence intervals, p-values, and sample sizes (N) for each condition at 7 dpf. Student’s t-test was used to calculate p-values for each condition relative non-ablated controls (0 mM Mtz). Bonferroni correction for multiple comparisons resulted in an adjusted alpha level of 0.01 (α=0.01). Two experimental repeats were performed for each condition and data pooled across replicates (Figure 1—source data 1). (b) Paired compound p-values relative to all control conditions in Figure 7—figure supplement 1. Student’s t-test was used to calculate p-values for each paired condition relative to ablated controls (+Mtz), BMN alone control and NEC alone control for all paired conditions. Bonferroni correction for multiple comparisons resulted in an adjusted significance level of 0.003 (α=0.003). Survival effects as shown in Figure 7—figure supplement 1 are provided for context (Figure 7—figure supplement 1—source data 1). Inhibitor abbreviations: BMN, talazoparib; NEC, necrostatin-1. Other abbreviations: CI, confidence interval; Mtz, Metronidazole; NA, not applicable. (c) Paired compound p-values relative to all control conditions in Figure 10. Student’s t-test was used to calculate p-values for each paired condition relative to ablated controls (+Mtz) and relevant individual compound controls (Cmpd A, top paired compound; Cmpd B, bottom paired compound). Bonferroni correction for multiple comparisons to +Mtz control resulted in an adjusted significance level of 0.002 (α=0.002); significance level for comparisons to individual compound controls was 0.05 (α=0.05). Survival effects as shown in Figure 10 are provided for context (Figure 10—source data 1). Lead compound abbreviations: WAR, Warfarin; CLO, Cloxyquin; CPO, Ciclopirox olamine; MIC, Miconazole; ZPT, Zinc pyrithione; DHA, Dihydroartemisinin; CHL, Chloroxine; CAL, Calcimycin; SUL, Sulindac; ART, Artemesinin; COR, Cortexolone; POS, positive control. Other abbreviations: CI, confidence interval; Mtz, Metronidazole.
Previously implicated neuroprotectants.
(a) Compounds tested as positive controls. List of 17 compounds previously reported as neuroprotectants in RP models tested for survival effects in rho:YFP-NTR zebrafish larvae using the primary screening protocol. (b) List of eliminated compounds. Compounds that were autofluorescent (precluding YFP signal detection) or lethal at the concentrations tested (10 mM to 0.625 mM). (c) List of 113 hit compounds. Hit compounds producing a SSMD score ≥1 in the primary screen ordered according to SSMD score. Drug names, concentrations producing SSMD ≥1, SSMD scores, SSMD effect types, and whether a dose-dependent trend was observed or not are shown. Yellow highlighted drugs were selected for confirmation testing. ‘'●” denotes confirmed lead compounds (source data). (d) On-label MOA for 113 hit compounds. Implicated MOA categories and subcategories are listed in order from most common to least common. The number of compounds per each category/subcategory are provided in the parentheses and compound names are listed.
Oligonucleotides used for sgRNA synthesis (gene knockdown) and qPCR primers.
Abbreviations: parp1, poly (ADP-ribose) polymerase 1; ripk1l, receptor (TNFRSF)-interacting serine-threonine kinase 1, like; casp3a: caspase 3, apoptosis-related cysteine peptidase a; casp3b: caspase 3, apoptosis-related cysteine peptidase b; tdp1, tyrosyl-DNA phosphodiesterase 1; actb1: actin, beta 1; rplp0: ribosomal protein, large, P0.